Dear Editor,Since its first description in South Africa in November 2021,the SARS-CoV-2 Omicron variant rapidly outcompeted the previously dominating Delta variant.Omicron is the fifth variant of concern(VOC).It conta...Dear Editor,Since its first description in South Africa in November 2021,the SARS-CoV-2 Omicron variant rapidly outcompeted the previously dominating Delta variant.Omicron is the fifth variant of concern(VOC).It contains an unusually high number of mutations compared to previous VOCs,especially in the viral Spike protein,and shows high transmissibility and efficient escape of neutralizing antibodies.展开更多
Dear Editor Effective vaccines and some antiviral agents against SARS-CoV-2,the causative agent of coronavirus disease 2019(COVID-19),have been developed.Nonetheless,additional therapeutics are needed since emerging S...Dear Editor Effective vaccines and some antiviral agents against SARS-CoV-2,the causative agent of coronavirus disease 2019(COVID-19),have been developed.Nonetheless,additional therapeutics are needed since emerging SARS-CoV-2 variants evade immunity induced by vaccination or previous infection and are resistant to therapeutic antibodies and fusion inhibitors.^(1)In addition,many patients experience prolonged post-acute sequelae of SARS-CoV-2.展开更多
基金supported by the DFG(CRCs 1279 and 1506)the EU commission(Fight-nCoV)the MWK and the BMBF(Restrict-SARS-CoV-2,IMMUNOMOD).
文摘Dear Editor,Since its first description in South Africa in November 2021,the SARS-CoV-2 Omicron variant rapidly outcompeted the previously dominating Delta variant.Omicron is the fifth variant of concern(VOC).It contains an unusually high number of mutations compared to previous VOCs,especially in the viral Spike protein,and shows high transmissibility and efficient escape of neutralizing antibodies.
基金supported by the DFG(CRC 1279)and the BMBF(IMMUNOMOD).
文摘Dear Editor Effective vaccines and some antiviral agents against SARS-CoV-2,the causative agent of coronavirus disease 2019(COVID-19),have been developed.Nonetheless,additional therapeutics are needed since emerging SARS-CoV-2 variants evade immunity induced by vaccination or previous infection and are resistant to therapeutic antibodies and fusion inhibitors.^(1)In addition,many patients experience prolonged post-acute sequelae of SARS-CoV-2.
